Literature DB >> 15711590

Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.

Lee L Eckhardt1, Sridharan Rajamani, Craig T January.   

Abstract

Drug induced long QT syndrome (LQTS) can lead to cardiac arrhythmias and sudden death, and has emerged as a worldwide problem. Most drugs that cause this are thought to directly block a specific cardiac ion channel (KCNH2 or hERG) that carries the rapidly activating delayed rectifier potassium current, I(Kr). In this issue of the British Journal of Pharmacology, evidence is presented to support a new mechanism for causing drug induced LQTS. The drug pentamidine, at near therapeutic concentrations that do not cause direct KCNH2 channel block, disrupts normal KCNH2 channel protein processing and maturation to reduce its surface membrane expression. This indirect mechanism for reducing I(Kr) is novel, and whether other drugs may cause similar protein trafficking abnormalities is largely unknown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711590      PMCID: PMC1576114          DOI: 10.1038/sj.bjp.0706143

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

Review 1.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Pentamidine reduces hERG expression to prolong the QT interval.

Authors:  Jason S Cordes; Zhuoqian Sun; David B Lloyd; Jenifer A Bradley; Alan C Opsahl; Mark W Tengowski; Xian Chen; Jun Zhou
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.

Authors:  Z Zhou; Q Gong; C T January
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 4.  Biology of cardiac arrhythmias: ion channel protein trafficking.

Authors:  Brian P Delisle; Blake D Anson; Sridharan Rajamani; Craig T January
Journal:  Circ Res       Date:  2004-06-11       Impact factor: 17.367

5.  Pentamidine-induced long QT syndrome and block of hERG trafficking.

Authors:  Yuri A Kuryshev; Eckhard Ficker; Lu Wang; Peter Hawryluk; Adrienne T Dennis; Barbara A Wible; Arthur M Brown; Jiesheng Kang; Xiao-Liang Chen; Kaoru Sawamura; William Reynolds; David Rampe
Journal:  J Pharmacol Exp Ther       Date:  2004-08-31       Impact factor: 4.030

6.  Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Authors:  Eckhard Ficker; Yuri A Kuryshev; Adrienne T Dennis; Carlos Obejero-Paz; Lu Wang; Peter Hawryluk; Barbara A Wible; Arthur M Brown
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

7.  Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.

Authors:  Benoit Drolet; Chantale Simard; Dan M Roden
Journal:  Circulation       Date:  2003-12-22       Impact factor: 29.690

  7 in total
  16 in total

Review 1.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

2.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

Review 3.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

Review 4.  Acquired long QT syndrome and phosphoinositide 3-kinase.

Authors:  Ira S Cohen; Richard Z Lin; Lisa M Ballou
Journal:  Trends Cardiovasc Med       Date:  2017-05-17       Impact factor: 6.677

5.  International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; A Breidenbach; K Bruse; H S Feldman; D Garnes; T Hammond; W Haverkamp; C January; J Koerner; C Lawrence; D Leishman; D Roden; J P Valentin; M A Vos; Y-Y Zhou; T Karluss; P Sager
Journal:  Br J Pharmacol       Date:  2008-08       Impact factor: 8.739

6.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells.

Authors:  Dong-fang Gu; Xue-lian Li; Zhi-ping Qi; Sha-shan Shi; Mei-qin Hu; Dong-min Liu; Cheng-bai She; Yan-jie Lv; Bao-xin Li; Bao-feng Yang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-05-08       Impact factor: 3.000

Review 8.  Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective.

Authors:  C E Pollard; J-P Valentin; T G Hammond
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

9.  In vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2.

Authors:  Sara F Ferreiro; Natalia Vilariño; M Carmen Louzao; K C Nicolaou; Michael O Frederick; Luis M Botana
Journal:  Toxicon       Date:  2014-10-05       Impact factor: 3.033

Review 10.  Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery.

Authors:  T P Barros; W K Alderton; H M Reynolds; A G Roach; S Berghmans
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.